Clinical trials (London, England)

Keyphrases

Publications

volume 21, number 3, 2024

Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus. Clinical trials (London, England) 21 (3) (2024)
Yong Zang, Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal, Xiongbin Lu
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical trials (London, England) 21 (3) (2024)
Ying Yuan, Heng Zhou, Suyu Liu
Statistical and practical considerations in planning and conduct of dose-optimization trials. Clinical trials (London, England) 21 (3) (2024)
Lucie Biard, Anaïs Andrillon, Rebecca B Silva, Shing M Lee
Dose optimization for cancer treatments with considerations for late-onset toxicities. Clinical trials (London, England) 21 (3) (2024)
Yong Zang, Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal, Xiongbin Lu
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical trials (London, England) 21 (3) (2024)
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus. Clinical trials (London, England) 21 (3) (2024)
Jingyi Zhang, Ruitao Lin, Xin Chen, Fangrong Yan
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical trials (London, England) 21 (3) (2024)
Lucie Biard, Anaïs Andrillon, Rebecca B Silva, Shing M Lee
Dose optimization for cancer treatments with considerations for late-onset toxicities. Clinical trials (London, England) 21 (3) (2024)
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus. Clinical trials (London, England) 21 (3) (2024)
Jingyi Zhang, Ruitao Lin, Xin Chen, Fangrong Yan
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical trials (London, England) 21 (3) (2024)
Yong Zang, Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal, Xiongbin Lu
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical trials (London, England) 21 (3) (2024)
Yong Zang, Beibei Guo, Yingjie Qiu, Hao Liu, Mateusz Opyrchal, Xiongbin Lu
Adaptive phase I-II clinical trial designs identifying optimal biological doses for targeted agents and immunotherapies. Clinical trials (London, England) 21 (3) (2024)
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus. Clinical trials (London, England) 21 (3) (2024)
Lucie Biard, Anaïs Andrillon, Rebecca B Silva, Shing M Lee
Dose optimization for cancer treatments with considerations for late-onset toxicities. Clinical trials (London, England) 21 (3) (2024)
Lucie Biard, Anaïs Andrillon, Rebecca B Silva, Shing M Lee
Dose optimization for cancer treatments with considerations for late-onset toxicities. Clinical trials (London, England) 21 (3) (2024)
Jingyi Zhang, Ruitao Lin, Xin Chen, Fangrong Yan
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical trials (London, England) 21 (3) (2024)
Codruta Chiuzan, Hakim-Moulay Dehbi
The 3 + 3 design in dose-finding studies with small sample sizes: Pitfalls and possible remedies. Clinical trials (London, England) 21 (3) (2024)
Peter F Thall, Elizabeth Garrett-Mayer, Nolan A Wages, Susan Halabi, Ying Kuen Cheung
Current issues in dose-finding designs: A response to the US Food and Drug Adminstration's Oncology Center of Excellence Project Optimus. Clinical trials (London, England) 21 (3) (2024)
Jingyi Zhang, Ruitao Lin, Xin Chen, Fangrong Yan
Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses. Clinical trials (London, England) 21 (3) (2024)
Julia Maués, Anne Loeser, Janice Cowden, Sheila Johnson, Martha Carlson, Shing Lee
The patient perspective on dose optimization for anticancer treatments: A new era of cancer drug dosing-Challenging the "more is better" dogma. Clinical trials (London, England) 21 (3) (2024)

volume 21, number 4, 2024

Salma Fahridin, Neeru Agarwal, Karen Bracken, Stephen Law, Rachael L Morton
The use of linked administrative data in Australian randomised controlled trials: A scoping review. Clinical trials (London, England) 21 (4) (2024)
David M Zahrieh, Blaize W Kandler, Jennifer G Le-Rademacher
The symbolic two-step method applied to cancer care delivery research: Safeguarding against designing an underpowered cluster randomized trial with a continuous outcome by accounting for the imprecision in the within- and between-center variation. Clinical trials (London, England) 21 (4) (2024)
Renate Le Marsney, Kerry Johnson, Jenipher Chumbes Flores, Shelley Coetzer, Jennifer Darvas, Carmel Delzoppo, Arielle Jolly, Kate Masterson, Claire Sherring, Hannah Thomson, Endrias Ergetu, Patricia Gilholm, Kristen S Gibbons
Assessing the impact of risk-based data monitoring on outcomes for a paediatric multicentre randomised controlled trial. Clinical trials (London, England) 21 (4) (2024)
Takashi Miyakoshi, Yuichiro Abe
Assessing the current utilization status of wearable devices in clinical research. Clinical trials (London, England) 21 (4) (2024)
Frank E Harrell
Commentary on van Lancker et al. Clinical trials (London, England) 21 (4) (2024)
Katarina Hedman, Vera Lisovskaja, Per Nyström
A safety estimand for late phase clinical trials where the analysis period varies over the subjects. Clinical trials (London, England) 21 (4) (2024)
Tessa-May Zirnsak, Ashley H Ng, Catherine Brasier, Richard Gray
Public involvement in Australian clinical trials: A systematic review. Clinical trials (London, England) 21 (4) (2024)
Guangyu Tong, Jiaqi Tong, Yi Jiang, Denise A Esserman, Michael O Harhay, Joshua L Warren
Hierarchical Bayesian modeling of heterogeneous outcome variance in cluster randomized trials. Clinical trials (London, England) 21 (4) (2024)
Frank E Harrell
Commentary on van Lancker et al. Clinical trials (London, England) 21 (4) (2024)
Salma Fahridin, Neeru Agarwal, Karen Bracken, Stephen Law, Rachael L Morton
The use of linked administrative data in Australian randomised controlled trials: A scoping review. Clinical trials (London, England) 21 (4) (2024)
Frank E Harrell
Commentary on van Lancker et al. Clinical trials (London, England) 21 (4) (2024)
Matthew J Gooden, Gina Norato, Katherine Landry, Sandra B Martin, Avindra Nath, Lauren Bowen Reoma
Rethinking the clinical research protocol: Lessons learned from the COVID-19 pandemic and recommendations for reducing noncompliance. Clinical trials (London, England) 21 (4) (2024)
Kelly Van Lancker, Frank Bretz, Oliver Dukes
Covariate adjustment in randomized controlled trials: General concepts and practical considerations. Clinical trials (London, England) 21 (4) (2024)
Matthew J Gooden, Gina Norato, Katherine Landry, Sandra B Martin, Avindra Nath, Lauren Bowen Reoma
Rethinking the clinical research protocol: Lessons learned from the COVID-19 pandemic and recommendations for reducing noncompliance. Clinical trials (London, England) 21 (4) (2024)
Dan-Yu Lin, Jianqiao Wang, Yu Gu, Donglin Zeng
Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials. Clinical trials (London, England) 21 (4) (2024)
Renate Le Marsney, Kerry Johnson, Jenipher Chumbes Flores, Shelley Coetzer, Jennifer Darvas, Carmel Delzoppo, Arielle Jolly, Kate Masterson, Claire Sherring, Hannah Thomson, Endrias Ergetu, Patricia Gilholm, Kristen S Gibbons
Assessing the impact of risk-based data monitoring on outcomes for a paediatric multicentre randomised controlled trial. Clinical trials (London, England) 21 (4) (2024)
Dan-Yu Lin, Jianqiao Wang, Yu Gu, Donglin Zeng
Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials. Clinical trials (London, England) 21 (4) (2024)
Peter Grabitz, Lana Saksone, Susanne Gabriele Schorr, Johannes Schwietering, Merlin Bittlinger, Jonathan Kimmelman
Research encouraging off-label use of quetiapine: A systematic meta-epidemiological analysis. Clinical trials (London, England) 21 (4) (2024)
Kelly Van Lancker, Frank Bretz, Oliver Dukes
Response to Harrell's commentary. Clinical trials (London, England) 21 (4) (2024)
David M Zahrieh, Blaize W Kandler, Jennifer G Le-Rademacher
The symbolic two-step method applied to cancer care delivery research: Safeguarding against designing an underpowered cluster randomized trial with a continuous outcome by accounting for the imprecision in the within- and between-center variation. Clinical trials (London, England) 21 (4) (2024)
Jijia Wang, Jing Cao, Chul Ahn, Song Zhang
A Bayesian adaptive design approach for stepped-wedge cluster randomized trials. Clinical trials (London, England) 21 (4) (2024)
Tessa-May Zirnsak, Ashley H Ng, Catherine Brasier, Richard Gray
Public involvement in Australian clinical trials: A systematic review. Clinical trials (London, England) 21 (4) (2024)
Guangyu Tong, Jiaqi Tong, Yi Jiang, Denise A Esserman, Michael O Harhay, Joshua L Warren
Hierarchical Bayesian modeling of heterogeneous outcome variance in cluster randomized trials. Clinical trials (London, England) 21 (4) (2024)
Tessa-May Zirnsak, Ashley H Ng, Catherine Brasier, Richard Gray
Public involvement in Australian clinical trials: A systematic review. Clinical trials (London, England) 21 (4) (2024)
Renate Le Marsney, Kerry Johnson, Jenipher Chumbes Flores, Shelley Coetzer, Jennifer Darvas, Carmel Delzoppo, Arielle Jolly, Kate Masterson, Claire Sherring, Hannah Thomson, Endrias Ergetu, Patricia Gilholm, Kristen S Gibbons
Assessing the impact of risk-based data monitoring on outcomes for a paediatric multicentre randomised controlled trial. Clinical trials (London, England) 21 (4) (2024)
Jijia Wang, Jing Cao, Chul Ahn, Song Zhang
A Bayesian adaptive design approach for stepped-wedge cluster randomized trials. Clinical trials (London, England) 21 (4) (2024)
Guangyu Tong, Jiaqi Tong, Yi Jiang, Denise A Esserman, Michael O Harhay, Joshua L Warren
Hierarchical Bayesian modeling of heterogeneous outcome variance in cluster randomized trials. Clinical trials (London, England) 21 (4) (2024)
Dan-Yu Lin, Jianqiao Wang, Yu Gu, Donglin Zeng
Evaluating treatment efficacy in hospitalized COVID-19 patients, with applications to Adaptive COVID-19 Treatment Trials. Clinical trials (London, England) 21 (4) (2024)
Salma Fahridin, Neeru Agarwal, Karen Bracken, Stephen Law, Rachael L Morton
The use of linked administrative data in Australian randomised controlled trials: A scoping review. Clinical trials (London, England) 21 (4) (2024)
Matthew J Gooden, Gina Norato, Katherine Landry, Sandra B Martin, Avindra Nath, Lauren Bowen Reoma
Rethinking the clinical research protocol: Lessons learned from the COVID-19 pandemic and recommendations for reducing noncompliance. Clinical trials (London, England) 21 (4) (2024)